IN8bio, Inc. presented new positive preclinical data from its induced pluripotent stem cell (iPSC) gamma-delta T cell platform at the Society for Immunotherapy of Cancer?s (SITC) 38th Annual Meeting. The data represents a significant advance in the development of the INB-500 iPSC program towards the development of allogeneic gamma-delta T cell therapies. The presented data underscores the platform?s ability to reprogram donor cells into iPSCs, expand them, and guide their differentiation into gamma-delta T cells through IN8bio?s proprietary process, which can be scaled for full GMP manufacturing.

Notably, the platform enables the differentiation into both Vd1+ and Vd2+ cell subtypes using cell-type specific processes. The iPSC-derived gamma-delta T cells underwent comprehensive characterization, encompassing morphological analysis, cell surface markers and functional assessment via tumor cell killing assays. Key findings include: iVd1+ gamma-delta T cells expressed the cell markers expected of innate gamma-delta T cells, including a strong capacity for cytokine release, indicating that the cells possess an effector phenotype.

To date, hundreds of millions of iVd1+ gamma-delta T cells have been produced from single iPSC clones at a low passage number. The cells demonstrated robust cytotoxic activity across a variety of cancer cell lines, including ovarian, glioblastoma (GBM), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) cell lines, potentially providing an allogeneic platform for a broad range of cancers. Cryopreservation did not impact the cells with the Vd1+ gamma-delta T cells showing comparable cytotoxicity to fresh cells, which allows them to be expanded and banked for potential on-demand clinical use.